Mediwound Ltd share price today

(MDWD)

Mediwound Ltd share price is $18.07 & ₹1,531.07 as on 6 Dec 2024, 2.30 'hrs' IST

$18.07

▲

0.04

(0.22%)

Market is closed - opens 8 PM, 06 Dec 2024

View live Mediwound Ltd share price in Dollar and Rupees. Guide to invest in Mediwound Ltd from India. Also see the sentimental analysis on Indian investors investing in Mediwound Ltd. Get details on the Indian mutual funds that are investing in Mediwound Ltd. Get Analyst recommendations and forecasts along with all the Mediwound Ltd's financials.

Mediwound Ltd share price movements

$18.07
$18.38
$18.07
0.03%
Downside
Day's Volatility :1.71%
Upside
1.69%
$8.81
$24.00
$18.07
51.25%
Downside
52 Weeks Volatility :63.29%
Upside
24.71%

Mediwound Ltd Returns

Period	Mediwound Ltd	Index (Russel 2000)
3 Months	9.01%	0.0%
6 Months	6.19%	0.0%
1 Year	95.2%	0.0%
3 Years	2.99%	-18.1%

Mediwound Ltd Key Statistics

in dollars & INR

Previous Close	$18.03
Open	$18.19
Today's High	$18.38
Today's Low	$18.065
Market Capitalization	$188.5M
Today's Volume	$73.3K
52 Week High	$24.0
52 Week Low	$8.81
Revenue TTM	$20.1M
EBITDA	$-14.5M
Earnings Per Share (EPS)	$-2.91
Profit Margin	-99.17%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-75.66%

How to invest in Mediwound Ltd from India?

It is very easy for Indian residents to invest directly in Mediwound Ltd from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Mediwound Ltd stock in both rupees (INR) and dollars (USD). Search for Mediwound Ltd or MDWD on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Mediwound Ltd or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Mediwound Ltd shares which would translate to 0.047 fractional shares of Mediwound Ltd as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Mediwound Ltd

125%

Period: Sep 6, 2024 to Dec 5, 2024. Change in 30 Days versus previous period

Search volume for Mediwound Ltd on INDmoney from India has grown in the last 30 days as on Dec 6, 2024. 125% more investors are searching Mediwound Ltd in the last 30 days versus the previous period.

Global Institutional Holdings in Mediwound Ltd

Investors Finance Co PLC
8.08%
Yelin Lapidot Holdings Management Ltd
6.96%
Rosalind Advisors, Inc.
5.82%
BlackRock Inc
3.60%
Balyasny Asset Management LLC
1.54%
Sargent Investment Group, LLC
1.09%

Analyst Recommendation on Mediwound Ltd

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Mediwound Ltd(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Mediwound Ltd

What analysts predicted

Upside of 60.49%

Current:

$18.07

Target:

$29.00

Insights on Mediwound Ltd

Decreasing Revenue
Revenue is down for the last 2 quarters, 5.06M → 4.35M (in $), with an average decrease of 14.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -6.30M → -10.28M (in $), with an average decrease of 63.1% per quarter
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.6% return, outperforming this stock by 39.9%

Mediwound Ltd Technicals Summary

Sell

Neutral

Buy

Mediwound Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Mediwound Ltd Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Mediwound Ltd	1.49%	6.19%	95.2%	2.99%	-14.97%
Regeneron Pharmaceuticals, Inc.	-8.09%	-23.99%	-10.23%	20.04%	108.5%
Biontech Se	5.61%	16.8%	14.99%	-61.28%	304.14%
Alnylam Pharmaceuticals, Inc.	-4.63%	65.6%	42.73%	40.34%	109.6%
Vertex Pharmaceuticals Incorporated	-6.83%	-3.58%	31.58%	126.94%	112.3%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Mediwound Ltd	NA	NA	-0.07	-3.26	-0.76	-0.16	NA	3.43
Regeneron Pharmaceuticals, Inc.	18.55	18.55	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.23	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Mediwound Ltd	Buy	$188.5M	-14.97%	NA	-99.17%
Regeneron Pharmaceuticals, Inc.	Buy	$83.0B	108.5%	18.55	33.61%
Biontech Se	Buy	$28.9B	304.14%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	109.6%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$120.6B	112.3%	32.84	-4.51%

About Mediwound Ltd

mediwound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. mediwound’s first innovative biopharmaceutical product, nexobrid®, received marketing authorization from the european medicines agency as well as the israeli and argentinian ministries of health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in europe israel and argentina. nexobrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissue. mediwound's second innovative product, escharex®, is a topical biological drug being developed for debridement of chronic and

Organization	Mediwound Ltd
Employees	100
CEO	Mr. Ofer Gonen B.Sc.
Industry	Health Technology

Management People of Mediwound Ltd

Name	Title
Mr. Ofer Gonen B.Sc.	Chief Executive Officer
Ms. Hani Luxenburg	Chief Financial Officer
Mr. Yaron Meyer Adv.	Executive VP, General Counsel & Corporate Secretary
Dr. Ety Klinger MBA, Ph.D.	Chief Research & Development Officer
Dr. Lior Rosenberg M.D.	Co-Founder
Dr. Shmulik Hess Ph.D.	COO & Chief Commercial Officer
Dr. Liron Gal	Executive Director of Manufacturing Science & Technology
Mr. Barry J. Wolfenson	Executive Vice President of Strategy & Corporate Development
Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc.	Chief Medical Officer

Important FAQs about investing in Mediwound Ltd from India :

What is Mediwound Ltd share price today?

Mediwound Ltd (MDWD) share price today is $18.07.

Can Indians buy Mediwound Ltd shares?

Yes, Indians can invest in the Mediwound Ltd (MDWD) from India.

With INDmoney, you can buy Mediwound Ltd at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Mediwound Ltd at zero transaction cost.

How can I buy Mediwound Ltd shares from India?

It is very easy to buy Mediwound Ltd from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Mediwound Ltd be purchased?

Yes, you can buy fractional shares of Mediwound Ltd with INDmoney app.

What are the documents required to start investing in Mediwound Ltd stocks?

To start investing in Mediwound Ltd, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.